Although CRE activity in epithelial- or fibroblast-specific peaks did not differ significantly between ER + /HER2 − and triple-negative breast cancer TNBC, the activity in immune-cell-specific peaks was higher in the TNBC samples than in the ER + /HER2 − samples (Fig. 2b, c). The gene discussed is ESR1; the disease is triple-negative breast carcinoma.